BRPI0514413C1 - sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento - Google Patents

sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento

Info

Publication number
BRPI0514413C1
BRPI0514413C1 BRPI0514413A BRPI0514413A BRPI0514413C1 BR PI0514413 C1 BRPI0514413 C1 BR PI0514413C1 BR PI0514413 A BRPI0514413 A BR PI0514413A BR PI0514413 A BRPI0514413 A BR PI0514413A BR PI0514413 C1 BRPI0514413 C1 BR PI0514413C1
Authority
BR
Brazil
Prior art keywords
salt
medicine
pharmaceutical composition
biphenyl compound
purification process
Prior art date
Application number
BRPI0514413A
Other languages
English (en)
Inventor
Rapta Miroslav
Colson Pierre-Jean
S Chao Robert
Original Assignee
Theravance Respiratory Co Llc
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Respiratory Co Llc, Theravance Inc filed Critical Theravance Respiratory Co Llc
Publication of BRPI0514413A publication Critical patent/BRPI0514413A/pt
Publication of BRPI0514413B1 publication Critical patent/BRPI0514413B1/pt
Publication of BRPI0514413C1 publication Critical patent/BRPI0514413C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

forma cristalina de um composto de bifenil a invenção fornece um sal cristalino do ácido 1,2-etanodissulfônico do éster 1- [2- (2-cloro-4-{ [(r) -2-hidroxi-2-(8-hidroxi-2-oxo-l, 2-dihidroquinolin-5-il) etilamino] metil}-5-rnetoxifenilcarbamoil) etil]piperidin-4-il do ácido bifenil-2-ilcarbâmico ou um solvato deste. esta invenção também fornece composições farmacêuticas compreendendo tal sal ou preparado usando tal sal, processos e intermediários para preparar tal sal; e métodos de uso de tal sal para tratar uma disfunção pulmonar.
BRPI0514413A 2004-08-16 2005-08-15 sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento BRPI0514413C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60180504P 2004-08-16 2004-08-16
US60/601,805 2004-08-16
PCT/US2005/029013 WO2006023454A1 (en) 2004-08-16 2005-08-15 Crystalline form of a biphenyl compound

Publications (3)

Publication Number Publication Date
BRPI0514413A BRPI0514413A (pt) 2008-06-10
BRPI0514413B1 BRPI0514413B1 (pt) 2019-04-16
BRPI0514413C1 true BRPI0514413C1 (pt) 2021-05-25

Family

ID=35687428

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514413A BRPI0514413C1 (pt) 2004-08-16 2005-08-15 sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento

Country Status (26)

Country Link
US (4) US7521558B2 (pt)
EP (1) EP1778672B1 (pt)
JP (2) JP5032990B2 (pt)
KR (1) KR101363352B1 (pt)
CN (1) CN101006077B (pt)
AR (1) AR051003A1 (pt)
AU (1) AU2005277601B2 (pt)
BR (1) BRPI0514413C1 (pt)
CA (1) CA2575874C (pt)
DK (1) DK1778672T3 (pt)
ES (1) ES2400958T3 (pt)
HK (1) HK1106227A1 (pt)
HR (1) HRP20130192T1 (pt)
IL (1) IL180853A (pt)
MA (1) MA28825B1 (pt)
MX (1) MX2007001688A (pt)
MY (1) MY141224A (pt)
NO (1) NO338770B1 (pt)
NZ (1) NZ552796A (pt)
PL (1) PL1778672T3 (pt)
PT (1) PT1778672E (pt)
RU (1) RU2381223C2 (pt)
SI (1) SI1778672T1 (pt)
TW (1) TWI374883B (pt)
WO (1) WO2006023454A1 (pt)
ZA (1) ZA200701057B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
BRPI0719270A2 (pt) * 2006-10-04 2014-03-11 Pfizer Ltd Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EA022030B1 (ru) 2009-04-14 2015-10-30 Глаксо Груп Лимитед Способ получения 1-[2-(2-хлор-4-формил-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN102405218B (zh) 2009-04-23 2014-06-04 施万制药 具蕈毒碱受体拮抗剂和β2 肾上腺素受体激动剂活性的二酰胺化合物
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013066616A1 (en) 2011-10-31 2013-05-10 Glaxo Wellcome Manufacturing Pte Ltd Pazopanib formulation
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EA201500651A1 (ru) 2012-12-18 2015-11-30 Альмираль, С.А. НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TW201835041A (zh) 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
WO2022175982A1 (en) * 2021-02-19 2022-08-25 Gbr Laboratories Private Limited A process for preparing batefenterol and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS596860B2 (ja) * 1975-05-19 1984-02-15 オオツカセイヤク カブシキガイシヤ ５−〔（２−アルキルアミノ−１−ヒドロキシ）アルキル〕カルボスチリル誘導体の製造法
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
EP1235802B1 (en) 1999-12-07 2005-07-13 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2004356517A (ja) 2003-05-30 2004-12-16 Ebara Corp 基板洗浄装置及び基板洗浄方法
US20050025718A1 (en) 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
KR20070057832A (ko) 2007-06-07
EP1778672A1 (en) 2007-05-02
MX2007001688A (es) 2007-04-23
RU2381223C2 (ru) 2010-02-10
NO338770B1 (no) 2016-10-17
US7521558B2 (en) 2009-04-21
ZA200701057B (en) 2008-08-27
US20060035931A1 (en) 2006-02-16
NZ552796A (en) 2010-09-30
BRPI0514413A (pt) 2008-06-10
SI1778672T1 (sl) 2013-04-30
JP5032990B2 (ja) 2012-09-26
CN101006077A (zh) 2007-07-25
TW200613296A (en) 2006-05-01
NO20071307L (no) 2007-04-11
PL1778672T3 (pl) 2013-05-31
AU2005277601A1 (en) 2006-03-02
DK1778672T3 (da) 2013-03-25
MA28825B1 (fr) 2007-08-01
HK1106227A1 (en) 2008-03-07
EP1778672B1 (en) 2012-12-19
CA2575874C (en) 2012-10-09
US8476299B2 (en) 2013-07-02
IL180853A (en) 2014-03-31
RU2007109598A (ru) 2008-09-27
US20090221638A1 (en) 2009-09-03
TWI374883B (en) 2012-10-21
US20130289281A1 (en) 2013-10-31
CA2575874A1 (en) 2006-03-02
HRP20130192T1 (hr) 2013-04-30
WO2006023454A1 (en) 2006-03-02
AU2005277601B2 (en) 2011-10-27
BRPI0514413B1 (pt) 2019-04-16
KR101363352B1 (ko) 2014-02-14
ES2400958T3 (es) 2013-04-15
JP2012121929A (ja) 2012-06-28
US20120283289A1 (en) 2012-11-08
MY141224A (en) 2010-03-31
AR051003A1 (es) 2006-12-13
IL180853A0 (en) 2007-07-04
US8754223B2 (en) 2014-06-17
US8101766B2 (en) 2012-01-24
JP2008513358A (ja) 2008-05-01
PT1778672E (pt) 2013-02-25
CN101006077B (zh) 2012-04-25

Similar Documents

Publication Publication Date Title
BRPI0514413C1 (pt) sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento
WO2007127297A3 (en) Crystalline forms of a dimethylphenyl compound
BRPI0906104A2 (pt) "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AR104288A2 (es) Forma cristalina i de la sal del ácido succínico de 1-[2-(2-cloro-4-[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil-5-metoxifenilcarbamoil)etil]piperidin-4-il éster del ácido bifenil-2-ilcarbámico, composiciones, combinaciones y procedimiento para su preparación
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
WO2001028996A3 (en) Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
NO20091560L (no) Biaryleterureaforbindelser
EP1887007A3 (en) Imidazo- and Thiazolopyridine as JAK3 Kinase Inhibitors
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
TW200714586A (en) Crystalline forms of a biphenyl compound
WO2008106130A3 (en) Tertiary amine substituted peptides useful as inhibitors of hcv replication
NO20063928L (no) Substituerte kinolinforbindelser
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
WO2008068615A8 (en) Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid
IL193771A (en) Preparations that act as protein inhibitors deliver cholesterol ester
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
MA32564B1 (fr) NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
WO2005123670A3 (en) Crystalline form of a substituted pyrrolidine compound
BRPI0519152A2 (pt) composto ou um sal ou derivado Éster farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, formulaÇÕes para tratar osteoporose e psorÍase, uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo, e, composiÇço farmacÊutica
NO20076396L (no) Substituert akrylamidderivat og farmasoytisk preparat som omfatter dette
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
NO20092413L (no) Pyrazolanaloger

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: THERAVANCE RESPIRATORY COMPANY, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2519 DE 16/04/2019, QUANTO A DATA DA PRIORIDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.